Amylyx To Appeal Against EMA Rejection Of ALS Drug Albrioza

 
• By Neena Brizmohun

Amylyx is standing by the clinical trial data it used to support its EU marketing application for its amyotrophic lateral sclerosis treatment, saying that the same data formed the basis of approvals for Albrioza in the US and Canada.

Thumbs down
The EMA said Amylyx's ALS drug should not be approved in the EU • Source: Shutterstock

More from Europe

More from Geography